Dow Tumbles 300 Points After US Economy Adds 263,000 Jobs
U.S. stocks traded lower this morning, with the Dow Jones falling more than 300 points on Friday following the release of jobs data for November.
Reported Late Thursday, Theratechnologies Announces Update From Ongoing TH1902 Study; Decided To Pause The Enrollment Of Patients In Its Phase 1 Clinical Trial Of Th1902; Plans To Submit An Amendment To Its Protocol To The U.S. FDA For Approval
Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers
Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.
Theratechnologies Is An Underappreciated HIV-Focused Company, Analyst Says
Cantor Fitzgerald has initiated coverage on Theratechnologies Inc (NASDAQ:THTX) with an Overweight rating and a price target of $9. Theratechnologies’ two HIV…
Cantor Fitzgerald Initiates Coverage On Theratechnologies with Overweight Rating, Announces Price Target of $9
Cantor Fitzgerald analyst Louis Chen initiates coverage on Theratechnologies (NASDAQ:THTX) with a Overweight rating and announces Price Target of $9.
Theratechnologies Q3 Sales $20.80M Beat $20.65M Estimate
Theratechnologies (NASDAQ:THTX) reported quarterly sales of $20.80 million which beat the analyst consensus estimate of $20.65 million by 0.73 percent. This is a 16.51 percent increase over sales of $17.85 million the
Theratechnologies’ Trogarzo Approved By FDA For 30-Second Intravenous (IV) Push, Simplifying HIV Treatment For Heavily Treatment-Experienced Population
Reduces maintenance dose from a 15-minute IV infusion to a 30-second, undiluted IV push every two weeks
Safety profile of Trogarzo® IV push similar to that of IV infusion
New method of
AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.